Director Declaration

Vectura Group plc

DIRECTOR DECLARATION

Chippenham, UK - 21 October 2015: In accordance with Listing Rule 9.6.14 (2) Vectura Group plc (LSE: VEC; "Vectura" or "the Company") announces that Dr. Susan Foden, Non-Executive Director of Vectura, is a Non-Executive Director of Evgen Pharma plc, which was admitted to AIM on 21 October 2015.

Enquiries

Notes for Editors:

About Vectura

Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth $44 billion worldwide.1

Vectura now has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura currently has disclosed development collaborations and licence agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company.

Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.

For further information, please visit Vectura's website at www.vectura.com.